Rut Isacson
- Oncology top 2%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Surgery top 10%
- Biomaterials top 5%
- Co-authors
- Alberto GabizónG BrufmanJ PaterRichard M. HansenPhilippe RougierJean‐Pierre PignonCynthia G. LeichmanBrian Weinerman
- Topics
- Cancer Treatment and Pharmacology (7 papers)Chemotherapy-induced cardiotoxicity and mitigation (4 papers)Lung Cancer Research Studies (3 papers)
- Cited by
- OncologyHepatologyBiomaterials
- Partner nations
- IsraelUnited States
In The Last Decade
Rut Isacson
22 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Oncology 1.3k
- Pulmonary and Respiratory Medicine 441
- Molecular Biology 378
- Surgery 340
- Biomaterials 296
Countries citing papers authored by Rut Isacson
This map shows the geographic impact of Rut Isacson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rut Isacson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rut Isacson more than expected).
Fields of papers citing papers by Rut Isacson
This network shows the impact of papers produced by Rut Isacson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rut Isacson. The network helps show where Rut Isacson may publish in the future.
Co-authorship network of co-authors of Rut Isacson
This figure shows the co-authorship network connecting the top 25 collaborators of Rut Isacson. A scholar is included among the top collaborators of Rut Isacson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rut Isacson. Rut Isacson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 38 | |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 9 | |
| 5 | 95 | |
| 6 | 2 | |
| 7 | 24 | |
| 8 | Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.breakdown → | 789 |
| 9 | 404 | |
| 10 | 386 | |
| 11 | 13 | |
| 12 | 129 | |
| 13 | 3 | |
| 14 | 15 | |
| 15 | 1 | |
| 16 | Treatment of primary and metastatic liver cancer using an implantable chemoinfusion pump. | 1 |
| 17 | Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas. | 1 |
| 18 | 2 | |
| 19 | 6 | |
| 20 | 3 |
About Rut Isacson
Rut Isacson is a scholar working on Oncology, Reproductive Medicine and Otorhinolaryngology, having authored 22 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Lung Cancer Research Studies (3 papers). The work is most often cited by research in Oncology (1.3k citations), Hepatology (205 citations) and Biomaterials (296 citations). Rut Isacson has collaborated with scholars based in Israel and United States. Frequent co-authors include Alberto Gabizón, G Brufman, J Pater, Richard M. Hansen, Philippe Rougier, Jean‐Pierre Pignon, Cynthia G. Leichman, Brian Weinerman, J. Fryer and Benny Zee. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.